US Stocks


REGENXBIO Inc. is a biotech company that develops gene therapy products to treat genetic defects and produce therapeutic proteins or antibodies. The company's lead product candidate, RGX-314, is in Phase III clinical trial for treating age-related macular degeneration. REGENXBIO also licenses its proprietary NAV Technology Platform to other companies and has collaborations with Neurimmune AG to develop innovative gene therapies.